瑞舒伐他汀对急性ST段抬高型心肌梗死冠脉介入治疗后动脉粥样硬化CRPTNF―α影响.docVIP

瑞舒伐他汀对急性ST段抬高型心肌梗死冠脉介入治疗后动脉粥样硬化CRPTNF―α影响 　　[摘要] 目的 探讨瑞舒伐他汀对急性ST段抬高型心肌梗死冠脉介入治疗后动脉粥样硬化、CRP、TNF-α的影响。 方法 选取入医院治疗的急性ST段抬高型心肌梗死患者88例患者作为研究对象，入院后均行冠脉介入治疗，采用随机分组将患者分为对照组和观察组，对照组取阿托伐他汀用药，观察组取瑞舒伐他汀用药，观察血脂水平、血浆炎性因子、颈动脉中层厚度（IMT）以及造影结果等。 结果 观察组治疗后CRP、TNF-α分别为（3.17±1.56）g/L、（0.98±0.56）μg/L均显著低于对照组，差异具有统计学意义（P0.05）。观察组治疗后TC、TG、LDL-C均显著高于对照组，HDL-C显著低于对照组，差异具有统计学意义（P0.05）。观察组治疗后MLD为（3.12±0.28）mm显著高于对照组，IMT为（0.72±0.35）mm显著低于对照组，差异具有统计学意义（P0.05）。 结论 与阿托伐他汀相比，STEMI患者PCI术后取瑞舒伐他汀用药，抗炎、降脂效果更优，可有效抑制支架内再狭窄率。 　　[关键词] ST段抬高型心肌梗死；冠脉介入术；瑞舒伐他汀；炎性因子 　　[中图分类号] R542.22 [文献标识码] B [文章编号] 2095-0616（2015）14-138-03 　　The influence of atherosclerosis， CRP， TNF-α after coronary intervention treatment of acute ST segment elevation myocardial infarction with rosuvastatin 　　CHEN Wei 　　Department of Cardiovascular Medicine， Baoan Peoples Hospital， Shenzhen 518101， China 　　[Abstract] Objective To explore the influence of atherosclerosis， CRP， TNF-α after coronary intervention treatment of acute ST segment elevation myocardial infarction with rosuvastatin. Methods 88 patients with acute ST segment elevation myocardial infarction （STEMI） in our hospital were selected as research subjects and were received coronary intervention treatment after admission. They were randomly allocated to control group which were given atorvastatin and observation group which were given rosuvastatin. Blood lipid level， plasma inflammatory cytokines， intima-media thickness （IMT） and angiographic results were observed. Results CRP and TNF-α in observation group after treatment were （3.17±1.56） g/L and （0.98±0.56） μg/L， which was significantly lower than those in control group. The difference was statistically significant （P0.05）. TC， TG and LDL-C in observation group were significantly higher than those in control group， and HDL-C in observation group was significantly lower than that in control group after treatment. The difference was statistically significant （P0.05）. MLD in observation group was （3.12±0.28） mm， which was